Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients.

Journal of the Egyptian National Cancer Institute - 14 Oct 2024

Hanbal Ahmed Talaat, El-Ashwah Shaimaa, Eladl Ahmed E, Shamaa Sameh, Saleh Layla M

Abstract excerpt

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma and is characterized by heterogeneity in biology and clinical behavior. Mutations in the myeloid differentiation primary response 88 (MYD88) are found in different lymphoproliferative disorders and are associated with variable clinical and prognostic impact. AIM: To investigate the frequency of MYD88 L265P mutation and its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Egypt

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymph Nodes

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to Prognosis

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 39397180
DOI: 10.1186/s43046-024-00237-z
PMCID: PMC13313871

Genes

MYD88

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients.PMID 39397180Read ↗

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.Semantic proximity Read ↗

Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.Semantic proximity Read ↗

MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.Semantic proximity Read ↗

MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.Semantic proximity Read ↗

Expression of MYD88 L265P Mutation in Subtypes of Diffuse Large B-Cell Lymphoma in the Pakistani Population.Semantic proximity Read ↗

MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.Semantic proximity Read ↗

MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma.Semantic proximity Read ↗

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphomaSemantic proximity Read ↗

The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.Semantic proximity Read ↗

MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphomaSemantic proximity Read ↗

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.